X4 Pharmaceuticals, Inc last reported quarterly results on Nov 5, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $1.8 million (+215.2% year over year) and diluted EPS of -$0.69. It usually reports 31–44 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 31–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
+215.2%
|
-30
+18.8%
|
-0.69
+87.4%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
29
|
0
+100.5%
|
0.04
+100.5%
|
|
Nov 13, 2024
44 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
|
Aug 8, 2024
39 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 7, 2024
37 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 9, 2023
40 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 10, 2023
41 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
|
May 4, 2023
34 days after quarter end
|
—
ended Mar 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- XFOR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1501697
- Former names
- Arsanis, Inc. (until Mar 13, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.